Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison Sells 1,715 Shares

Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Becton, Dickinson and Company Stock Down 0.3 %

Shares of Becton, Dickinson and Company stock opened at $233.81 on Thursday. The business has a 50-day moving average of $238.75 and a 200-day moving average of $240.71. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64. The company has a market capitalization of $67.55 billion, a PE ratio of 55.41, a P/E/G ratio of 1.93 and a beta of 0.43. Becton, Dickinson and Company has a 1-year low of $229.40 and a 1-year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.29. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.73 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The company’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the firm earned $2.98 earnings per share. As a group, equities analysts forecast that Becton, Dickinson and Company will post 12.94 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 90.05%.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of hedge funds have recently bought and sold shares of the company. Jeppson Wealth Management LLC grew its stake in Becton, Dickinson and Company by 4.0% in the third quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock worth $266,000 after purchasing an additional 40 shares in the last quarter. U.S. Capital Wealth Advisors LLC grew its stake in Becton, Dickinson and Company by 3.4% in the third quarter. U.S. Capital Wealth Advisors LLC now owns 1,310 shares of the medical instruments supplier’s stock worth $339,000 after purchasing an additional 43 shares in the last quarter. Value Partners Investments Inc. grew its stake in Becton, Dickinson and Company by 5.2% in the third quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock worth $225,000 after purchasing an additional 43 shares in the last quarter. Ridgewood Investments LLC grew its stake in Becton, Dickinson and Company by 1.5% in the first quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock worth $731,000 after purchasing an additional 43 shares in the last quarter. Finally, Key Client Fiduciary Advisors LLC lifted its holdings in Becton, Dickinson and Company by 2.6% in the first quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock worth $424,000 after acquiring an additional 43 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Raymond James raised their price objective on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Barclays raised their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research note on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $280.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.